{
  "title": "M21-1, Part V, Subpart iii, Chapter 8, Section B - Disabilities of the Breast",
  "url": "https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180879/M21-1-Part-V-Subpart-iii-Chapter-8-Section-B-Disabilities-of-the-Breast",
  "content": "<-- Previous Section\nNext Section -->\nOverview\nIn This Section\nThis section contains the topic \"\nDisabilities of the Breast\n.\"\n1\n.\nDisabilities of the Breast\nIntroduction\nThis topic contains information about evaluating disabilities of the breast, including\nmalignant neoplasms of the breast\ndisfigurement due to benign or malignant neoplasms\nfibrocystic breast disease\nelective breast surgery\n, and\ngynecomastia\n.\nChange Date\nMay 14, 2018\nV.iii.8.B.1.a\n.\nMalignant Neoplasms of the Breast\nMalignant neoplasms of male or female breast tissue (\n38 CFR 4.116, diagnostic code (DC) 7630\n) are evaluated at 100 percent for active cancer.\nFor female Veterans, consider corresponding entitlement to special monthly compensation (SMC).\nImportant\n:  Separate 100-percent evaluations will be assigned for both active gynecological cancer and active breast cancer.  Metastasis of a gynecological cancer or breast cancer to a different body system will also be evaluated separately.\nReferences\n:  For more information on\ntemporary total evaluations for cancers, see\nM21-1, Part VIII, Subpart iv, 8.D.3.e\nevaluating malignant neoplasms and associated impairments, see\nM21-1, Part V, Subpart ii, 3.D.5.a and b\n, and\nconsidering SMC (k) due to loss of breast tissue, see\n38 CFR 3.350(a)\n, and\nM21-1, Part VIII, Subpart iv, 4.A.4.k\n.\nV.iii.8.B.1.b\n.\nDisfigurement Due to Benign or Malignant Neoplasms\nDo not evaluate disfigurement due to benign or malignant neoplasms of the breast analogous to\n38 CFR 4.118, DC 7800\nunless there is actual disfigurement of the head, face, or neck.  DC 7800 is for evaluation of disfigurement of the head, face, or neck only.\nV.iii.8.B.1.c\n.\nFibrocystic Breast Disease\nDo not routinely award service connection (SC) for fibrocystic breast disease.  Although this condition is termed a disease, it is actually a physiologic finding that is generally acute and transient.  In the absence of associated pathology, SC is not warranted.  Additionally, fibrocystic breasts are not associated with increased risk of breast cancer unless the changes are associated with atypical hyperplasia.\nExamples of associated pathology that\nmay\nwarrant SC for fibrocystic breast disease are\npersistent lumps or thickening requiring surgical excision, or\nfibrocystic breast changes with associated atypical hyperplasia.\nUse the table below to determine when SC for pathology associated with claimed fibrocystic breast disease is warranted as well as the proper DC to use in the evaluation.\nIf the service treatment records show …\nAnd medical evidence shows …\nThen award SC for …\nfibrocystic breasts\ncontinuous symptoms and/or nexus to subsequent post-service excision of persistent lumps or thickening\nresiduals of surgery under appropriate DCs including\nthe\n38 CFR 4.118, DC 7800\nseries for scars, and\n38 CFR 4.116, DC 7626\nfor breast, surgery of.\nfibrocystic breasts\nthe (in-service or post-service) development of atypical hyperplasia associated with the fibrocystic breasts\nsubsequent development of breast cancer, and\nnexus between the fibrocystic breasts with associated atypical hyperplasia and the development of breast cancer\nbreast cancer and/or residuals under appropriate DCs including\n38 CFR 4.116, DC 7627\n, or\n38 CFR 4.116, DC 7626\n.\nV.iii.8.B.1.d\n.\nElective Breast Surgery\nBreast surgeries that are not medically necessitated, such as reduction mammoplasty for cosmetic purposes and any expected residual effects thereof, are\nnot\nsubject to SC. Such procedures are considered elective surgeries and therefore do not meet the provisions of a disease or injury incurred coincident with service.\nImportant\n:  If reduction mammoplasty is recommended to alleviate physical discomfort, such as back, shoulder, or neck pain, SC should be considered on the basis of aggravation only, and if so established, SMC (k) would be payable if the resultant tissue loss meets the requirements of the statute.\nReferences\n:  For more information about\nprinciples relating to SC, see\n38 CFR 3.303\n, and\nM21-1, Part V, Subpart ii, 2.A\naggravation of pre-service disability, see\n38 CFR 3.306\n, and\nM21-1, Part V, Subpart ii, 2.C\n, and\nentitlement to SMC (k), see\n38 CFR 3.350(a)\n, and\nM21-1, Part VIII, Subpart iv, 4.A.4\n.\nV.iii.8.B.1.e\n.\nGynecomastia\nSC may be established for gynecomastia when the evidence shows that it was incurred in or caused by military service.  However, consideration must be given to whether there is clear evidence that the condition existed prior to service.\nEvaluate gynecomastia depending on symptoms and/or pre- or post-surgical resection status under\n38 CFR 4.116, DC 7626\n38 CFR. 4.116, DC 7631\n, or\n38 CFR 4.118, DC 7804/7805\n.\nNote\n:  Under\n38 CFR 4.116, DC 7626\n, no more than a noncompensable evaluation can be assigned as there is no significant alteration in size or form since the removal of excess tissue results in a return to breast size within normal limits for a human male.\n<-- Previous Section\nNext Section -->\nTo Top",
  "content_html": "<div class=\"article-content\">\n<div compile-custom=\"article.content\" ng-aria=\"articleContent\"><p class=\"ng-scope\"></p><p class=\"ng-scope\" style=\"text-align: right\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 11px\"><a articleid=\"554400000180511\" articlename=\"M21-1, Part V, Subpart iii, Chapter 8, Section A - Disabilities of the Gynecological System\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180511/M21-1-Part-V-Subpart-iii-Chapter-8-Section-A-Disabilities-of-the-Gynecological-System\">&lt;-- Previous Section</a>  <a articleid=\"554400000180513\" articlename=\"M21-1, Part V, Subpart iii, Chapter 9 - Hematologic and Lymphatic Systems\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180513/M21-1-Part-V-Subpart-iii-Chapter-9-Hematologic-and-Lymphatic-Systems\">Next Section --&gt;</a></span></span></p><h2 class=\"ng-scope\"><a id=\"top\" name=\"top\"><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\">Overview</span></span></a></h2><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">In This Section</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">This section contains the topic \"<a href=\"#1\" target=\"_self\">Disabilities of the Breast</a>.\"</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">       </span></span></p></div><h2 class=\"ng-scope\"><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\">1<a id=\"1\" name=\"1\">.</a>  Disabilities of the Breast</span></span></h2><p class=\"ng-scope\"> <br/> </p><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/><div></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Introduction</span></span></span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">This topic contains information about evaluating disabilities of the breast, including</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#1a\" target=\"_self\">malignant neoplasms of the breast </a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#1b\" target=\"_self\">disfigurement due to benign or malignant neoplasms </a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#4c\" target=\"_self\">fibrocystic breast disease</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#1d\" target=\"_self\">elective breast surgery</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#1e\" target=\"_self\">gynecomastia</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Change Date</span></span></strong></span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">May 14, 2018</span></span></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">V.iii.8.B.1.a<a id=\"1a\" name=\"1a\">.</a>  Malignant Neoplasms of the Breast</span> </span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Malignant neoplasms of male or female breast tissue (<a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=235eda989da86f124d10851943899cce&amp;mc=true&amp;node=se38.1.4_1116&amp;rgn=div8\" target=\"_blank\">38 CFR 4.116, diagnostic code (DC) 7630</a>) are evaluated at 100 percent for active cancer. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">For female Veterans, consider corresponding entitlement to special monthly compensation (SMC).</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Important</em></strong>:  Separate 100-percent evaluations will be assigned for both active gynecological cancer and active breast cancer.  Metastasis of a gynecological cancer or breast cancer to a different body system will also be evaluated separately. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>References</em></strong>:  For more information on</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">temporary total evaluations for cancers, see <a articleid=\"554400000177543\" articlename=\"M21-1, Part VIII, Subpart iv, Chapter 8, Section D - Other Temporary Total Evaluations\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177543/M21-1-Part-VIII-Subpart-iv-Chapter-8-Section-D-Other-Temporary-Total-Evaluations\">M21-1, Part VIII, Subpart iv, 8.D.3.e</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">evaluating malignant neoplasms and associated impairments, see <a articleid=\"554400000180489\" articlename=\"M21-1, Part V, Subpart ii, Chapter 3, Section D - Evaluating Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180489/M21-1-Part-V-Subpart-ii-Chapter-3-Section-D-Evaluating-Disabilities\">M21-1, Part V, Subpart ii, 3.D.5.a and b</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">considering SMC (k) due to loss of breast tissue, see</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=546be1e864685b4584786ea651ec7827&amp;mc=true&amp;node=se38.1.3_1350&amp;rgn=div8\" target=\"_blank\">38 CFR 3.350(a)</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a articleid=\"554400000177480\" articlename=\"M21-1, Part VIII, Subpart iv, Chapter 4, Section A - Special Monthly Compensation (SMC)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177480/M21-1-Part-VIII-Subpart-iv-Chapter-4-Section-A-Special-Monthly-Compensation-SMC\">M21-1, Part VIII, Subpart iv, 4.A.4.k</a>.</span></span></div></li></ul></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">V.iii.8.B.1.b<a id=\"1b\" name=\"1b\">.</a>  Disfigurement Due to Benign or Malignant Neoplasms</span> </span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Do not evaluate disfigurement due to benign or malignant neoplasms of the breast analogous to <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=68490608d79a4870dab0180df9f932af&amp;mc=true&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118, DC 7800</a> unless there is actual disfigurement of the head, face, or neck.  DC 7800 is for evaluation of disfigurement of the head, face, or neck only.  </span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.8.B.1.c<a id=\"1c\" name=\"1c\">.</a>  <strong>Fibrocystic Breast Disease</strong></span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Do not routinely award service connection (SC) for fibrocystic breast disease.  Although this condition is termed a disease, it is actually a physiologic finding that is generally acute and transient.  In the absence of associated pathology, SC is not warranted.  Additionally, fibrocystic breasts are not associated with increased risk of breast cancer unless the changes are associated with atypical hyperplasia.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Examples of associated pathology that <em>may</em> warrant SC for fibrocystic breast disease are</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">persistent lumps or thickening requiring surgical excision, or</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">fibrocystic breast changes with associated atypical hyperplasia.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Use the table below to determine when SC for pathology associated with claimed fibrocystic breast disease is warranted as well as the proper DC to use in the evaluation.</span></span></div><div></div><table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"width: 510px; border-spacing: 1px; border-collapse: revert;\" summary=\"This is an if-and-then table.  Column 1 provides the first criteria, column 2 provides the second criteria, and column 3 provides instructions to determine when SC for pathology associated with claimed fibrocystic breast disease is warranted as well as the proper DC to use in the evaluation.\" width=\"510\"><thead><tr><th scope=\"col\" style=\"width: 174px; padding: 1px;\"><div style=\"text-align: left\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>If the service treatment records show …</strong></span></span></div></th><th scope=\"col\" style=\"width: 162px; padding: 1px;\"><div style=\"text-align: left\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>And medical evidence shows …</strong></span></span></div></th><th scope=\"col\" style=\"width: 174px; padding: 1px;\"><div style=\"text-align: left\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Then award SC for … </strong></span></span></div></th></tr></thead><tbody><tr><td style=\"width: 174px; vertical-align: top; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">fibrocystic breasts</span></span></div></td><td style=\"width: 162px; vertical-align: top; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">continuous symptoms and/or nexus to subsequent post-service excision of persistent lumps or thickening</span></span></div></td><td style=\"width: 174px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">residuals of surgery under appropriate DCs including</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">the <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=34f5be5bd7a22201187835c9489d743d&amp;mc=true&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118, DC 7800</a> series for scars, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=235eda989da86f124d10851943899cce&amp;mc=true&amp;node=se38.1.4_1116&amp;rgn=div8\" target=\"_blank\">38 CFR 4.116, DC 7626</a> for breast, surgery of.</span></span></div></li></ul></td></tr><tr><td style=\"width: 174px; vertical-align: top; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">fibrocystic breasts</span></span></div></td><td style=\"width: 162px; padding: 1px;\"><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">the (in-service or post-service) development of atypical hyperplasia associated with the fibrocystic breasts</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">subsequent development of breast cancer, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">nexus between the fibrocystic breasts with associated atypical hyperplasia and the development of breast cancer</span></span></div></li></ul></td><td style=\"width: 174px; vertical-align: top; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">breast cancer and/or residuals under appropriate DCs including</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=235eda989da86f124d10851943899cce&amp;mc=true&amp;node=se38.1.4_1116&amp;rgn=div8\" target=\"_blank\">38 CFR 4.116, DC 7627</a>, or</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=235eda989da86f124d10851943899cce&amp;mc=true&amp;node=se38.1.4_1116&amp;rgn=div8\" target=\"_blank\">38 CFR 4.116, DC 7626</a>.</span></span></div></li></ul></td></tr></tbody></table><div></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.8.B.1.d<a id=\"1d\" name=\"1d\">.</a>  Elective Breast Surgery</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Breast surgeries that are not medically necessitated, such as reduction mammoplasty for cosmetic purposes and any expected residual effects thereof, are <em>not</em> subject to SC. Such procedures are considered elective surgeries and therefore do not meet the provisions of a disease or injury incurred coincident with service.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Important</em></strong>:  If reduction mammoplasty is recommended to alleviate physical discomfort, such as back, shoulder, or neck pain, SC should be considered on the basis of aggravation only, and if so established, SMC (k) would be payable if the resultant tissue loss meets the requirements of the statute.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>References</em></strong>:  For more information about</span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">principles relating to SC, see</span></span><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=faf94b4af1bc629e74a43b1bdf68a224&amp;mc=true&amp;node=se38.1.3_1303&amp;rgn=div8\" target=\"_blank\">38 CFR 3.303</a>, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a articleid=\"554400000014553\" articlename=\"M21-1, Part IV, Subpart ii, Chapter 2, Section B - Failure to Report for Review Examinations\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014553/M21-1-Part-IV-Subpart-ii-Chapter-2-Section-B-Failure-to-Report-for-Review-Examinations\">M21-1, Part V, Subpart ii, 2.A</a></span></span></li></ul></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">aggravation of pre-service disability, see</span></span><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=c2324cb278e04b66400e0e3d539f72a1&amp;mc=true&amp;node=se38.1.3_1306&amp;rgn=div8\" target=\"_blank\">38 CFR 3.306</a>, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a articleid=\"554400000180483\" articlename=\"M21-1, Part V, Subpart ii, Chapter 2, Section C - In-Service Aggravation of a Pre-Service Disability\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180483/M21-1-Part-V-Subpart-ii-Chapter-2-Section-C-In-Service-Aggravation-of-a-Pre-Service-Disability\">M21-1, Part V, Subpart ii, 2.C</a>, and</span></span></li></ul></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">entitlement to SMC (k), see</span></span><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=c2324cb278e04b66400e0e3d539f72a1&amp;mc=true&amp;node=se38.1.3_1350&amp;rgn=div8\" target=\"_blank\">38 CFR 3.350(a)</a>, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a articleid=\"554400000177480\" articlename=\"M21-1, Part VIII, Subpart iv, Chapter 4, Section A - Special Monthly Compensation (SMC)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177480/M21-1-Part-VIII-Subpart-iv-Chapter-4-Section-A-Special-Monthly-Compensation-SMC\">M21-1, Part VIII, Subpart iv, 4.A.4</a>.</span></span></li></ul></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.8.B.1.e<a id=\"1e\" name=\"1e\">.</a>  Gynecomastia</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">SC may be established for gynecomastia when the evidence shows that it was incurred in or caused by military service.  However, consideration must be given to whether there is clear evidence that the condition existed prior to service.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Evaluate gynecomastia depending on symptoms and/or pre- or post-surgical resection status under<span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=2be2e518f0995935b547f32619996b84&amp;mc=true&amp;node=se38.1.4_1116&amp;rgn=div8\" target=\"_blank\">38 CFR 4.116, DC 7626</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=2be2e518f0995935b547f32619996b84&amp;mc=true&amp;node=se38.1.4_1116&amp;rgn=div8\" target=\"_blank\">38 CFR. 4.116, DC 7631</a>, or</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=2be2e518f0995935b547f32619996b84&amp;mc=true&amp;node=se38.1.4_1118&amp;rgn=div8\" target=\"_blank\">38 CFR 4.118, DC 7804/7805</a>.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Note</em></strong>:  Under <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=2be2e518f0995935b547f32619996b84&amp;mc=true&amp;node=se38.1.4_1116&amp;rgn=div8\" target=\"_blank\">38 CFR 4.116, DC 7626</a>, no more than a noncompensable evaluation can be assigned as there is no significant alteration in size or form since the removal of excess tissue results in a return to breast size within normal limits for a human male. </span></span></span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><p class=\"ng-scope\" style=\"text-align: right\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 11px\"><a articleid=\"554400000180511\" articlename=\"M21-1, Part V, Subpart iii, Chapter 8, Section A - Disabilities of the Gynecological System\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180511/M21-1-Part-V-Subpart-iii-Chapter-8-Section-A-Disabilities-of-the-Gynecological-System\">&lt;-- Previous Section</a>  <a articleid=\"554400000180513\" articlename=\"M21-1, Part V, Subpart iii, Chapter 9 - Hematologic and Lymphatic Systems\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180513/M21-1-Part-V-Subpart-iii-Chapter-9-Hematologic-and-Lymphatic-Systems\">Next Section --&gt;</a></span></span></p><p class=\"ng-scope\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#top\" target=\"_self\"><span style=\"font-size: 11px\">To Top</span></a></span></p><p class=\"ng-scope\"></p></div>\n</div>",
  "external_links": [
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=235eda989da86f124d10851943899cce&mc=true&node=se38.1.4_1116&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=34f5be5bd7a22201187835c9489d743d&mc=true&node=se38.1.4_1118&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=c2324cb278e04b66400e0e3d539f72a1&mc=true&node=se38.1.3_1306&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=c2324cb278e04b66400e0e3d539f72a1&mc=true&node=se38.1.3_1350&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=faf94b4af1bc629e74a43b1bdf68a224&mc=true&node=se38.1.3_1303&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=235eda989da86f124d10851943899cce&mc=true&node=se38.1.4_1116&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=2be2e518f0995935b547f32619996b84&mc=true&node=se38.1.4_1116&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=2be2e518f0995935b547f32619996b84&mc=true&node=se38.1.4_1118&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=546be1e864685b4584786ea651ec7827&mc=true&node=se38.1.3_1350&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=68490608d79a4870dab0180df9f932af&mc=true&node=se38.1.4_1118&rgn=div8"
  ],
  "scraped_at": "2025-06-16T22:45:25.998509",
  "next_section": "https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180513/M21-1-Part-V-Subpart-iii-Chapter-9-Hematologic-and-Lymphatic-Systems"
}